XVIVO Project

Vibativ

XVIVO Client

GlaxoSmithKline

XVIVO Tags

MRSA infection, Vibativ, XVIVO

Bookmark and Share

 
XVIVO Project Details

GlaxoSmithKline commissioned XVIVO to create a mechanism of action animation for Theravance’s new class of antibiotic, Vibativ developed to stop serious MRSA infections in hospital settings. Vibativ works by preventing bacterial ribosomes from making proteins, which replicating bacteria require to effectively build new cell walls. Bacteria will run out of cell wall material in the replication process effectively killing them.

Working With XVIVO

I reviewed the video this morning and think it looks truly exceptional—I had high expectations to begin with and you have actually exceeded them.”
CEO, Threshold Pharmaceuticals

XVIVO Project Inquiry?
XVIVO Project Details